Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the launch of the newly enhanced Cortellis CMC Intelligence™ solution, featuring a new post-approval variations module. The module for post-approval variations covers regulatory changes across multiple countries, offering meticulously curated requirements to streamline tracking. With this update, pharmaceutical, biotech, and generics companies can effortlessly navigate the regulatory process and prioritize essential actions.
$100 Invested In This Stock 15 Years Ago Would Be Worth $900 Today
Lowe’s Companies (NYSE:LOW) has outperformed the market over the past 15 years by 8.97% on an annualized basis…
